There are now 3 studies of the 4th vaccine (2nd booster) dose, all with short term follow-up 1. Good antibody response, safe, limited effectiveness vs symptomatic infections in health care professionals nejm.org/doi/full/10.10…
2. ~4-fold protection vs severe illness for 60+ age group, at 12+ days after 4th shot, compared with 3- shots (≥ 4 months out) medrxiv.org/content/10.110…
3. 78% reduction of mortality for age 60+ among >550,00 people at 40 days for 4-doses vs 3-doses (≥4 months out) researchsquare.com/article/rs-147…
4. For the 3rd shot there was a 90% reduction of mortality for people age 50+, same source @ClalitHealth, as the new 4th shot report nejm.org/doi/full/10.10…
The 4th shot is already underway in the UK. Meanwhile, millions of Americans of advanced age are well past 6 months from getting their 3rd shot, with substantial waning of protection, with no plan yet. /1
Reduction in neutralizing antibodies after mRNA vaccines at 5 months /2 nejm.org/doi/full/10.10…
Israel's findings of protection for the 3rd and 4th dose are quite different, both in people age 60+, early read out at just 12+ days
3rd shot (Delta wave): ~15-fold protection vs severe illness
4th shot (Omicron wave): ~4-fold protection vs severe illness
Whereas the 3rd shot had durable protection vs severe illness for 4+ months, the 4th (vs Omicron, w/ far more immune evasion), may be limited
They've worked remarkably well vs severe disease, with a 3rd shot that restored effectiveness at ~95% vs hospitalization and death.
But the virus has continued to evolve, the antigenic distance between Omicron BA.1 and BA.2 is as far as Beta to Gamma.
When South Korea, a model country for the pandemic, has >400,000 new cases in a day, leading the world per capita, you take notice. Tests 4X the US with <1/6th the population. BA.2 is 26% as of this week's report.
Very high 2-shot vaxx 87%, 3-shot 63%. The pandemic isn't over.
Relative to Hong Kong, it's death rate is very low. Boosters more than double. Great coverage of age 60+ No Sinovac vaccines.
BTW Hong Kong's booster 30% rate now exceeds the US (29%)
Relative to European countries with a BA.2-related hospitalization increase, South Korea's (BA.1) is more pronounced